Prana Biotechnology Ltd. (Nasdaq: PRAN) will present pre-clinical evidence for PBT434 as a first-in-class disease modifying therapy to treat Parkinsonian movement disorders at the 13th International Conference for Alzheimer's and Parkinson's Diseases in Vienna. The stock price climbed 92 cents to close at $3.40.
Prana Biotechnology to present data
March 30, 2017 at 17:28 PM EDT
